Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Savolitinib in NSCLC: progress in the MET exon 14 journey998
Concerns regarding a suggested long COVID paradigm – Authors' reply492
Rituximab for connective tissue disease-associated interstitial lung disease383
Broad protection from SARS-CoV-2 variants without antigen matching307
The burden of tuberculosis in Libya246
European Respiratory Society International Congress 2022246
US Senate committee investigates asthma inhaler prices243
Major gaps in childhood pneumonia research priorities remain231
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress224
Opioids bring peace to patients with IPF cough217
Correction to Lancet Respir Med 2024; 12: 129–40217
Video laryngoscopy is not the nemesis of direct laryngoscopy211
Postoperative CPAP after major abdominal surgery204
Impact of Myanmar's earthquake on respiratory health192
Predicted bodyweight—a misleading metric for tidal volume titration?189
Concerns about PRISm187
Eat or heat: fuel poverty and childhood respiratory health185
Predatory publishers appear in PubMed (and your inbox)183
Australia bans engineered stone to prevent silicosis181
Chronic obstructive pulmonary disease: 10 years of precision-guided success178
Interstitial lung disease: a decade of progress and hope177
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?175
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros174
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop170
Long COVID: systemic inflammation and obesity as therapeutic targets170
Thoracentesis: an old story and some new sources163
FLiRTing with danger as SARS-CoV-2 variants evolve162
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership161
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis159
GOLD report: 2022 update158
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials156
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study156
Advancing precision medicine for acute respiratory distress syndrome153
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis146
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study144
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial144
Vaccination in the world's top athletes142
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts142
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials142
Correction to Lancet Respir Med 2025; 13: 244–55139
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta138
Correction to Lancet Respir Med 2021; 9: 1275–87138
Trump administration decimates worker health oversight136
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis134
Correction to Lancet Respir Med 2022; 10: 972–84128
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply124
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges123
Claudio Castanos—leader in cystic fibrosis care in Argentina123
Priorities for NICE in health and social care123
US EPA signals renewed regulatory scrutiny of toxic air pollution121
Solid and semi-solid perspectives in thoracic surgery119
Improving lifelong respiratory health after preterm birth115
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study114
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m113
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial112
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts111
Chronic cough as a disease: implications for practice, research, and health care110
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials106
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial105
Extracorporeal cardiopulmonary resuscitation: not why, but how105
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis105
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study104
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial101
Genetic associations and lung function in IPF: unexpected answers, persistent questions99
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co98
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis98
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub98
Association of SARS-CoV-2 infection and persistence with long COVID96
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial96
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO94
Unveiling a hidden phenotype of early tuberculosis92
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s92
Spirometry in female individuals – Authors' reply91
Health effects from climate-driven events: lessons learnt91
Choice overload for RSV prevention—how to form your opinion90
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing89
Pre-COPD: an evolving concept with practice potential88
Tackling tuberculosis: what lies beneath the surface?85
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma84
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO83
Correction to Lancet Respir Med 2023; 11: 1064–7483
Underappreciated causes of obstructive lung disease81
COP27 Climate Change Conference: urgent action needed for Africa and the world81
Opioid use and sleep apnoea81
0.29816603660583